RxDoctor Payments Data

Kimberly Feltner, DO

Internal Medicine · Malvern, PANPI 1073913596

Payments from drug & device makers

$1,690in general payments, 2019–2025

Across 30 payments — averaging $56.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$367
  • Neurocrine Biosciences, Inc.$249
  • Sun Pharmaceutical Industries Inc.$152
  • Axonics, Inc.$130
  • Otsuka America Pharmaceutical, Inc.$125
  • AstraZeneca$125
  • plus $542 from 7 others

What the payments were for

  • Food & beverage$1,690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,690 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$346,052
Medicare patients
701
Services billed
3,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban569$243,909
XifaxanRifaximin33$60,351
JanuviaSitagliptin Phosphate111$54,142
XareltoRivaroxaban102$51,050
MyrbetriqMirabegron71$31,115
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$25,164
EntrestoSacubitril/Valsartan66$22,164
Atorvastatin Calcium1,265$19,295
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr37$18,731
TrulicityDulaglutide16$16,582
JardianceEmpagliflozin38$16,373
Breo ElliptaFluticasone/Vilanterol32$15,947
FarxigaDapagliflozin Propanediol30$13,531
Gabapentin694$12,478
XiidraLifitegrast16$11,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$116$243,909569 claims
AstraZenecaFarxiga$125$13,53130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Malvern

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →